FDC Ltd.
Snapshot View

View in App

Prices View details >>

261.05 +0.50 ▲0.2%

07 February 2023, 04:01:00 PM
Volume: 6,543

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.fdcindia.com
Market Cap 4,313.66 Cr.
Enterprise Value(EV) 4,311.70 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 10.17 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 25.67 Trailing Twelve Months Ending 2022-09
Industry PE 32.80 Trailing Twelve Months Ending 2022-09
Book Value / Share 114.55 Trailing Twelve Months Ending 2022-09
Price to Book Value 2.28 Calculated using Price: 261.05
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 16.59 Cr. 165,910,084 Shares
FaceValue 1
Company Profile
FDC Limited is among India's leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialised formulations, and among the world's foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Over its long history of 85 years, the Company has maintained a distinguished reputation for high-quality, affordable products and built a market-leading brand portfolio.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.19%
1 Week
-1.93%
1 Month
-4.31%
3 Month
-15.15%
6 Month
-4.06%
1 Year
-14.69%
2 Year
-9.50%
5 Year
+2.51%
10 Year
+182.37%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 16.63 16.64 16.72 16.03 13.63 12.48 16.03 18.36 11.71
Return on Capital Employed (%) 27.12 23.02 23.11 21.51 19.00 17.49 21.56 23.74 15.78
Return on Assets (%) 13.26 13.34 13.97 12.00 9.03 8.20 10.43 11.85 7.59

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 845 936 1,082 1,270 1,276 1,445 1,547 1,734 1,957 1,901
Non Curr. Liab. 31 24 20 217 211 229 315 300 391 33
Curr. Liab. 196 188 163 389 480 497 565 622 690 365
Minority Int. 0 0 0
Equity & Liab. 1,072 1,148 1,266 1,876 1,968 2,172 2,427 2,655 3,038 2,297
Non Curr. Assets 619 646 742 958 977 1,113 1,181 1,303 1,620 1,281
Curr. Assets 452 502 523 918 991 1,058 1,245 1,352 1,418 1,016
Misc. Exp. not W/O 0
Total Assets 1,072 1,148 1,266 1,876 1,968 2,172 2,427 2,655 3,038 2,297

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 846 889 994 1,014 1,075 1,091 1,344 1,333 1,528 1,622
Other Income 42 46 39 50 51 43 69 97 76 54
Total Income 888 935 1,033 1,064 1,126 1,134 1,413 1,430 1,604 1,677
Total Expenditure -641 -691 -766 -770 -848 -860 -1,051 -999 -1,274 -1,410
PBIDT 246 244 268 294 278 274 362 431 330 267
Interest -3 -2 -1 -1 -1 -1 -3 -3 -3 -3
Depreciation -25 -39 -34 -35 -35 -33 -37 -38 -37 -38
Taxation -83 -56 -63 -63 -67 -67 -80 -87 -73 -57
Exceptional Items -6 -1 -2
PAT 135 148 169 189 174 170 240 301 216 168
Minority Interest 0 0 0
Share Associate
Other Related Items
Consolidated Net Profit 135 148 169 189 174 170 240 301 216 169
Adjusted EPS 8 8 9 11 10 10 14 18 13 10

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 150 150 128 174 154 150 112 250 207 162
Cash Fr. Inv. -107 -55 -89 -73 -144 20 -120 -98 -77 -145
Cash Fr. Finan. -63 -75 -48 -97 0 -169 0 -142 -129 -10
Net Change -20 19 -9 4 11 1 -8 10 1 7
Cash & Cash Eqvt 4 23 15 16 27 28 20 30 30 38

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 69.35 69.35 69.35 69.35 69.36 69.36 69.50 69.49 69.49
Public 30.65 30.65 30.65 30.65 30.64 30.64 30.51 30.51 30.51
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Tue, 31 Jan 2023
Board Meeting Intimation for Intimation Of Board Meeting & Closure Of The Trading Window
FDC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve the Unaudited Financial Results along with the Limited Review Report of the Company for the quarter ended December31 2022. Further in accordance with Code of Conduct adopted by the Company SEBI (Prohibition of Insider Trading) (Amendment) Regulations 2018 and vide our Intimation letter dated December 28 2022 the Trading Window of the Company has been closed for all the Designated Persons Connected Persons and their Immediate Relatives from Sunday January 01 2023 till 48 hours after the declaration of Unaudited Financial Results for the quarter ended December 31 2022.
Sat, 07 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Please find enclosed the certificate issued by the Registrar and Share Transfer Agent of the Company i.e. Link Intime India Pvt. Ltd. regarding the details of the securities dematerialized /rematerialized during the quarter ended on December 31 2022 as required under regulation 74 (5) of the SEBI (Depositories and Participants) Regulation 2018.
Wed, 28 Dec 2022
Closure of Trading Window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 & Amendments thereon and in compliance with Companys Code of Conduct for the Prevention of Insider Trading and Code of Fair Disclosure the Trading Window for dealing in Securities of the Company for all the Designated Persons Connected Persons and their Immediate Relative(s) shall remain closed from Sunday January 01 2023 until 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter and nine months ending on December 31 2022. The date of Board Meeting of the Company for consideration and approval of the Unaudited Financial Results for the quarter and nine months ending December 31 2022 will be intimated in due course.

Technical Scans View Details >>

Tue, 07 Feb 2023
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease in 3 Months High Decrease in 3 Months
Closing Near 20 SMA Closing Near 20 SMA
William %R Trending Down William %R Trending Down
Bearish Harami Cross Bearish Harami Cross

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 241,289.12 1,005.65 -1.7%
Cipla Ltd. 83,256.90 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. 73,968.14 4,441.90 +2.1%
Divi's Laboratories Ltd. 72,982.62 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. 62,135.10 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. 51,898.92 1,533.45 -0.4%
Zydus Lifesciences Ltd. 48,525.07 479.40 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 57.29 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-12 31.56 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.30 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-12 30.45 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 74.00 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.45 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-12 23.54 479.40 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.36 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-12 3.67 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.36 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-12 5.87 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.38 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.14 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.81 479.40 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 0.04 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 479.40 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 479.40 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 479.40 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 479.40 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 479.40 +2.0%

FAQ's On FDC Ltd.

What is FDC share price?
Can I buy FDC shares now?
What is the Market Cap of FDC?
What are the key metrics to analyse FDC?
What is the 52 Week High and Low of FDC?
What is the trend of FDC share price?